aibioKardigan files for IPO, plans Nasdaq Global Market listing as KARD
Tickers KARD
Kardigan filed an S-1 for an IPO that would list on the Nasdaq Global Market as KARD. The filing leaves the share count and price range blank, reports $287.1 million of cash and investments, and still says there is substantial doubt about its ability to continue as a going concern.
Key facts
- Company
- Kardigan, Inc. (NASDAQ: KARD)
- News type
- Financings
- Primary source
- Kardigan, Inc. S-1 (2026-05-26)
Kardigan, Inc. filed a Form S-1 registration statement with the Securities and Exchange Commission on May 26, 2026 for an initial public offering of its common stock. There is no public market for the shares. Kardigan has applied to list on the Nasdaq Global Market under the symbol KARD and says it believes it will meet Nasdaq's listing standards when the offering is complete. The offering is contingent on that listing.
Banks, counsel and structure
The cover names J.P. Morgan, Jefferies, Leerink Partners and TD Cowen as underwriters. The number of shares, the price range and the net proceeds are blank, so the filing does not yet say how much Kardigan expects to raise. The underwriters hold a 30-day option to buy additional shares. At the company's request they have reserved up to 5% of the shares for directors, officers, certain employees and other associated persons, sold through J.P. Morgan Securities LLC in a directed share program. The cover lists Goodwin Procter LLP and Latham & Watkins LLP for copies, without saying which acts for the company and which for the underwriters.
The company had 40,393,745 shares outstanding at March 31, 2026, after its redeemable convertible preferred stock converted into 29,987,476 common shares. It will have voting and non-voting common stock; the non-voting shares will not be listed, and none will be outstanding after the offering.
Going concern, despite the cash
The S-1 says management and the auditor have concluded there is substantial doubt about Kardigan's ability to continue as a going concern. At March 31, 2026 it held cash, cash equivalents and short-term investments of $287.1 million. Even so, it says its capital resources will not support operations for at least twelve months from May 26, 2026. It warns that substantial doubt may continue even after the offering, and that stockholders may lose some or all of their investment.
The losses are rising. Kardigan reported a net loss of $56.1 million for the three months ended March 31, 2026, against $18.0 million a year earlier, and $191.9 million for 2025 against $88.7 million for 2024. The accumulated deficit was $337.2 million.
The pipeline
Kardigan calls itself a clinical-stage company with a limited operating history, which it says may make its business hard to evaluate. It was incorporated in Delaware in August 2023 as EnCarda, Inc. and took its current name in December 2024. It describes three "late-stage" therapies, although the trials named are Phase 2 or Phase 2b/3.
Danicamtiv is an investigational oral myosin activator for genetic dilated cardiomyopathy caused by variants in the MYH7 and TTN genes. It has been evaluated in 10 completed clinical studies and is in the KINSHIP-DCM Phase 2b/3 adaptive, randomized, placebo-controlled trial. Ataciguat, an oral once-daily soluble guanylate cyclase activator aimed at slowing calcific aortic valve stenosis in moderate disease, is in the KATALYST-AV Phase 2b trial. Tonlamarsen, a liver-directed antisense drug given monthly by injection, targets angiotensinogen to manage blood pressure in acute severe hypertension after hospitalization. The company says it is supported by robust clinical data and is in the KARDINAL-ASH Phase 2 trial.
The company also relies on Prolaio, a data platform that uses wearable sensors and FDA-regulated devices to collect patient data during trials. The filing concedes the approach is novel and may not deliver the efficiencies or regulatory acceptance it hopes for. It also notes dependence on third parties for data from earlier preclinical studies and clinical trials.
The people and the money
Chief executive Tassos Gianakakos is a former CEO of MyoKardia and a co-founder of Prolaio, Inc.; chief medical officer Jay Edelberg, M.D., Ph.D., is also a co-founder. The filing names ARCH Venture Partners, HRTG Partners, Perceptive Advisors, T. Rowe Price and Fidelity Management & Research among its investors.
Kardigan plans to use net proceeds with existing cash to fund the clinical development of the three drugs and other research, with any remainder for general purposes. It says it will need more funding even if the offering succeeds. The filing does not state the offering size or price, so investors cannot yet compare a valuation with these losses.